Last reviewed · How we verify
Ketanest®S
Ketanest®S is a rapid-acting anesthetic that blocks NMDA receptors in the central nervous system to produce dissociative anesthesia and analgesia.
Ketanest®S is a rapid-acting anesthetic that blocks NMDA receptors in the central nervous system to produce dissociative anesthesia and analgesia. Used for Induction and maintenance of general anesthesia, Procedural sedation and analgesia.
At a glance
| Generic name | Ketanest®S |
|---|---|
| Also known as | Esketamine |
| Sponsor | Chengdu Brilliant Pharmaceutical Co., Ltd. |
| Drug class | NMDA receptor antagonist; dissociative anesthetic |
| Target | NMDA receptor (N-methyl-D-aspartate receptor) |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Ketanest®S (ketamine S-enantiomer) is an NMDA receptor antagonist that produces dissociative anesthesia by interrupting sensory input to the cerebral cortex while maintaining airway reflexes and respiratory drive. The S-enantiomer formulation offers improved pharmacokinetics and potentially faster recovery compared to racemic ketamine, making it suitable for induction and maintenance of anesthesia in surgical and procedural settings.
Approved indications
- Induction and maintenance of general anesthesia
- Procedural sedation and analgesia
Common side effects
- Emergence reactions (dissociative phenomena)
- Increased heart rate and blood pressure
- Dizziness or vertigo
- Nausea and vomiting
- Transient visual disturbances
Key clinical trials
- The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery (PHASE3)
- Histopathological, Biochemical And Electrophysiological Evaluation Of Single Or Combined Use Of Diode Laser/Steroid Treatment On Facial Nerve Injury (EARLY_PHASE1)
- Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter (PHASE2)
- Methadone and Ketamine for Neuropathic Pain Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketanest®S CI brief — competitive landscape report
- Ketanest®S updates RSS · CI watch RSS
- Chengdu Brilliant Pharmaceutical Co., Ltd. portfolio CI